YC-1;CS-2261;Nsc728165;LIFICIGUAT;Lificiguat(YC-1);YC-1(Lificiguat);YC 1 (pharMaceutical);Lificiguat, 10 mM in DMSO;YC-1, guanylyl cyclase activator;YC-1 - CAS 170632-47-0 - Calbiochem
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen.
YC-1 has been used as a hypoxia-inducible factor 1α (HIF-1α) inhibitor:
to reduce hypoxia induced Jagged1 expression in cardiomyocytes (CMs)
to study its effect on progenitor expansion and CD34+ and side population (SP) cell phenotype and on the proliferation rate of cells with an ability to form long term colony forming units
to study its effect on regulating sphingosine 1-phosphate (S1P) bound to albumin induced plasminogen activator inhibitor 1 (PAI-1) expression by activating Rho/ Rho-associated protein kinase (ROCK) pathway.
Allgemeine Beschreibung
A nitric oxide-independent, superoxide-sensitive activator of soluble guanylyl cyclase. Inhibits platelet adhesion to collagen and acts as an antithrombotic agent. Reported to reduce HIF-1α levels and xenograft growth.
Biochem/physiol Actions
YC-1 activates soluble guanylyl cyclase and prevents platelet aggregation and vascular contraction. It has a potential to treat circulation disorders. YC-1 also has an ability to inhibit hypoxia-inducible factor 1α (HIF-1α) activity in vitro. It acts as a potential antiangiogenic anticancer agent.